Back to resultsHigh-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma (MATRix)
Primary Purpose
Diffuse Large B-cell-lymphoma
Status
Unknown status
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Sponsored by
About this trial
This is an interventional treatment trial for Diffuse Large B-cell-lymphoma
Eligibility Criteria
Inclusion Criteria:
- Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma
- Age 18-65 years irrespective of ECOG or 66-70 years (with ECOG Performance Status ≤2)
- Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
- Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy
- Disease exclusively located in the CNS
- At least one measurable lesion
- Previously untreated patients (previous or ongoing steroid treatment admitted)
- Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during study participation
- Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease
ADDITIONAL RANDOMIZATION CRITERIA
- Sufficient stem cell harvest (≥ 5 x 106 CD34+ cells/kg of body weight)
- Complete remission, unconfirmed complete remission or partial remission
- Central pathology results confirming local results
Exclusion Criteria:
- Congenital or acquired immunodeficiency
- Systemic lymphoma manifestation (outside the CNS)
- Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord
- Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years
- Previous Non-Hodgkin lymphoma at any time
- Inadequate bone marrow (platelet count decreased ≥CTC grade 1, anemia ≥CTC grade 1, neutrophil count decreased ≥CTC grade 1), renal (creatinine clearance <60 ml/min), cardiac (ejection fraction decreased ≥CTC grade 2), or hepatic function (blood bilirubin increased ≥CTC grade 2, alanine aminotransferase increased ≥CTC grade 2, aspartate aminotransferase increased ≥CTC grade 2 or gamma-GT increased ≥CTC grade 2)
- HBsAg, anti-HBc or HCV positivity
- HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency
- Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study
- Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease)
- Severe non-compensated pulmonary disease (IVC <55%, DLCO <40%)
- Third space fluid accumulation >500 ml
- Hypersensitivity to study treatment or any component of the formulation
- Taking any medications likely to cause interactions with the study medication
- Known or persistent abuse of medication, drugs or alcohol
- Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative
- Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator
- Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- Concurrent (or planned) pregnancy or lactation
- Fertile patients refusing to use safe contraceptive methods during the study
Sites / Locations
- University Hospital Freiburg - Department for Hematology, Oncology and Stem cell TransplantionRecruiting
- Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-StihlRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Arm A
Arm B
Arm Description
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle: Rituximab 375 mg/m²/d i.v. (d0,5) Methotrexate 3.5 g/m² i.v. (d1) Cytarabine 2 x 2 g/m²/d i.v. (d2-3) Thiotepa 30 mg/m² i.v. (d4) Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks): Rituximab 375 mg/m²/d i.v. (d0) Dexamethasone 40 mg/d i.v. (d1-3) Etoposide 100 mg/m²/d i.v. (d1-3) Ifosfamide 1500 mg/m²/d i.v. (d1-3) Carboplatin 300 mg/m² i.v. (d1)
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle: Rituximab 375 mg/m²/d i.v. (d0,5) Methotrexate 3.5 g/m² i.v. (d1) Cytarabine 2 x 2 g/m²/d i.v. (d2-3) Thiotepa 30 mg/m² i.v. (d4) Consolidation Treatment High-dose chemotherapy Carmustine* 400 mg/m² i.v. (d-6) Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4)) Autologous Stem Cell Transplantation (d0) *if not available at study site, Busulfan can be administered instead: Busulfan 3,2 mg/kg/d i.v. (d-8-(-7)) Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4)) Autologous Stem Cell Transplantation (d0)
Outcomes
Primary Outcome Measures
The primary outcome measure PFS will be measured by the number of events (PD, relapse or death from any cause) within the treatment arms
Progression-free survival PFS:
Response Assessment III at the end of study treatment (EOT) visit and every imaging diagnostic assessments during follow-up period: during year 1-2: every 3 month
Secondary Outcome Measures
The secondary outcome measure CR will be assessed on day 60 after randomization using the IPCG response criteria
Response will be measured by the IPCG response criteria.
The secondary outcome measure Response duration will be measured by the time from CR, CRu or PR until relapse or PD using the IPCG response criteria
Response duration observation times for patients where the event of interest was not observed, will be censored at the time last seen alive. Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol.
year 1-2: every 3 month
The secondary outcome OS is measured as time from randomization until death of any cause
Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol.
year 1-2: every 3 month
Number of patients with (Serious) adverse events as assessed by CTCAE v4.0
After this time period, only SAEs judged by the investigator to be related to at least one of investigational products will be reported
Number of patients with treatment related toxicity as assessed by CTCAE v4.0
If an abnormal parameter is not listed in the toxicity table, an AE must be documented
Number of patients with neurotoxicity assessed by MMSE, EORTC QLQ-BN20 and the neuro-psychological battery
Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol
Full Information
NCT ID
NCT02531841
First Posted
August 14, 2015
Last Updated
August 24, 2015
Sponsor
University Hospital Freiburg
Collaborators
German Federal Ministry of Education and Research, International Extranodal Lymphoma Study Group (IELSG)
1. Study Identification
Unique Protocol Identification Number
NCT02531841
Brief Title
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Acronym
MATRix
Official Title
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Unknown status
Study Start Date
July 2014 (undefined)
Primary Completion Date
November 2017 (Anticipated)
Study Completion Date
December 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Freiburg
Collaborators
German Federal Ministry of Education and Research, International Extranodal Lymphoma Study Group (IELSG)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy against conventional consolidating therapy with 2 cycles of conventional chemotherapy with R-DeVIC (rituximab, dexamethasone, etoposide, ifosfamide, carboplatin).
Detailed Description
Trial purpose and rationale Primary central nervous system lymphoma (PCNSL) is a highly aggressive disease with rising incidence over the past 30 years. Similar to other hematological diseases, the rationale for consolidation in PCNSL is the elimination of minimal residual disease. The efficacy of WBRT, which is the current standard for consolidation after HD-MTX-based systemic treatment, is being compared to HDT-ASCT in the ongoing IELSG-32 trial.
High-dose chemotherapy with carmustine or busulfan and thiotepa followed by autologous stem cell transplantation has been shown to be feasible and highly effective in newly diagnosed eligible patients, but also in the salvage situation.
The question we aim to answer is whether HDT-ASCT is superior to conventional therapy as consolidation after intensified immunochemotherapy in newly diagnosed PCNSL.
Rationale for this study:
Based on previously obtained good results from the treatment of recurrent or refractory PCNSL the DeVIC protocol was chosen for conventional consolidation treatment. This protocol, originally designed as a salvage protocol for aggressive NHL, crosses the blood-brain barrier and consists of multidrug resistant unrelated agents.
Treatment plan and procedure
Interventions
Induction treatment 4 cycles (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d 0,5)
Methotrexate 3,5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4)
Patients with PD after two cycles, SD/PD after four cycles of induction therapy or insufficient stem-cell harvest after three cycles are ineligible for randomization.
Consolidation Arm A 2 cycles of R-DeVIC (every 3 weeks):
Rituximab 375 mg/m²/d i.v. (d0)
Dexamethasone 40 mg/d i.v. (d1-3)
Etoposide 100 mg/m²/d i.v. (d1-3)
Ifosfamide 1500 mg/m²/d i.v. (d1-3)
Carboplatin 300 mg/m² i.v. (d1)
Consolidation Arm B
High-dose chemotherapy (HDT-ASCT):
Carmustine* 400 mg/m² i.v. (d-6)
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
* if carmustine is not available at the investigation site, busulfan can be administered instead:
Busulfan 3,2 mg/kg/d (d-8-(-7))
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diffuse Large B-cell-lymphoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Arm A
Arm Type
Active Comparator
Arm Description
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4)
Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):
Rituximab 375 mg/m²/d i.v. (d0)
Dexamethasone 40 mg/d i.v. (d1-3)
Etoposide 100 mg/m²/d i.v. (d1-3)
Ifosfamide 1500 mg/m²/d i.v. (d1-3)
Carboplatin 300 mg/m² i.v. (d1)
Arm Title
Arm B
Arm Type
Active Comparator
Arm Description
Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4)
Consolidation Treatment High-dose chemotherapy
Carmustine* 400 mg/m² i.v. (d-6)
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
*if not available at study site, Busulfan can be administered instead:
Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
Intervention Type
Drug
Intervention Name(s)
Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)
Other Intervention Name(s)
Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®
Intervention Description
Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
Rituximab 375 mg/m²/d i.v. (d0)
Dexamethasone 40 mg/d i.v. (d1-3)
Etoposide 100 mg/m²/d i.v. (d1-3)
Ifosfamide 1500 mg/m²/d i.v. (d1-3)
Carboplatin 300 mg/m² i.v. (d1)
Intervention Type
Drug
Intervention Name(s)
Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Other Intervention Name(s)
TEPADINA®-CARMUBRIS®-Busilvex®
Intervention Description
4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation
High-dose chemotherapy (HDT-ASCT):
Carmustine* 400 mg/m² i.v. (d-6)
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
* if carmustine is not available at the investigation site, busulfan can be administered instead:
Busulfan 3,2 mg/kg/d (d-8-(-7))
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
Primary Outcome Measure Information:
Title
The primary outcome measure PFS will be measured by the number of events (PD, relapse or death from any cause) within the treatment arms
Description
Progression-free survival PFS:
Response Assessment III at the end of study treatment (EOT) visit and every imaging diagnostic assessments during follow-up period: during year 1-2: every 3 month
Time Frame
PFS is defined as the time from randomization until PD or relapse or death from any cause up to 24 months after end of treatment
Secondary Outcome Measure Information:
Title
The secondary outcome measure CR will be assessed on day 60 after randomization using the IPCG response criteria
Description
Response will be measured by the IPCG response criteria.
Time Frame
CR will be determined on day 60 after randomization
Title
The secondary outcome measure Response duration will be measured by the time from CR, CRu or PR until relapse or PD using the IPCG response criteria
Description
Response duration observation times for patients where the event of interest was not observed, will be censored at the time last seen alive. Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol.
year 1-2: every 3 month
Time Frame
Time from CR, CRu or PR until relapse or PD up to 24 months after end of treatment
Title
The secondary outcome OS is measured as time from randomization until death of any cause
Description
Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol.
year 1-2: every 3 month
Time Frame
OS is defined as time from randomization until death of any cause up to 24 months after end of treatment
Title
Number of patients with (Serious) adverse events as assessed by CTCAE v4.0
Description
After this time period, only SAEs judged by the investigator to be related to at least one of investigational products will be reported
Time Frame
All SAEs that occur starting from the first administration of the study medication until day 60 after randomization.
Title
Number of patients with treatment related toxicity as assessed by CTCAE v4.0
Description
If an abnormal parameter is not listed in the toxicity table, an AE must be documented
Time Frame
All toxicities that occur starting from the first administration of the study medication until day 60 after randomization.
Title
Number of patients with neurotoxicity assessed by MMSE, EORTC QLQ-BN20 and the neuro-psychological battery
Description
Timepoints of evaluation are defined as every assessment during follow up period in accordance with the protocol
Time Frame
All parameters of neurotoxicity that occur starting from the first administration of the study medication up to 24 months after end of treatment.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma
Age 18-65 years irrespective of ECOG or 66-70 years (with ECOG Performance Status ≤2)
Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy
Disease exclusively located in the CNS
At least one measurable lesion
Previously untreated patients (previous or ongoing steroid treatment admitted)
Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during study participation
Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease
ADDITIONAL RANDOMIZATION CRITERIA
Sufficient stem cell harvest (≥ 5 x 106 CD34+ cells/kg of body weight)
Complete remission, unconfirmed complete remission or partial remission
Central pathology results confirming local results
Exclusion Criteria:
Congenital or acquired immunodeficiency
Systemic lymphoma manifestation (outside the CNS)
Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord
Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years
Previous Non-Hodgkin lymphoma at any time
Inadequate bone marrow (platelet count decreased ≥CTC grade 1, anemia ≥CTC grade 1, neutrophil count decreased ≥CTC grade 1), renal (creatinine clearance <60 ml/min), cardiac (ejection fraction decreased ≥CTC grade 2), or hepatic function (blood bilirubin increased ≥CTC grade 2, alanine aminotransferase increased ≥CTC grade 2, aspartate aminotransferase increased ≥CTC grade 2 or gamma-GT increased ≥CTC grade 2)
HBsAg, anti-HBc or HCV positivity
HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency
Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study
Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease)
Severe non-compensated pulmonary disease (IVC <55%, DLCO <40%)
Third space fluid accumulation >500 ml
Hypersensitivity to study treatment or any component of the formulation
Taking any medications likely to cause interactions with the study medication
Known or persistent abuse of medication, drugs or alcohol
Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative
Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator
Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Concurrent (or planned) pregnancy or lactation
Fertile patients refusing to use safe contraceptive methods during the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabeth Schorb, PhD
Phone
0049761270
Ext
33210
Email
elisabeth.schorb@uniklinik-freiburg.de
First Name & Middle Initial & Last Name or Official Title & Degree
Elvira Burger
Phone
0049761270
Ext
73780
Email
elvira.burger@uniklinik-freiburg.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerald Illerhaus, PhD
Organizational Affiliation
Representative of Sponsor
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Freiburg - Department for Hematology, Oncology and Stem cell Transplantion
City
Freiburg
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
79106
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juergen Finke, PhD
Phone
+49761270
Ext
34080
Email
juergen.finke@uniklinik-freiburg.de
First Name & Middle Initial & Last Name & Degree
Elisabeth Schorb, PhD
Phone
+49761270
Ext
33210
Email
elisabeth.schorb@uniklinik-freiburg.de
Facility Name
Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-Stihl
City
Stuttgart
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
70174
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gerald Illerhaus, PhD
Phone
+49 711 278
Ext
30400
Email
G.Illerhaus@klinikum-stuttgart.de
First Name & Middle Initial & Last Name & Degree
Kristina Mikesch, PhD
Phone
+49 711 278
Ext
30403
Email
k.mikesch@klinikum-stuttgart.de
12. IPD Sharing Statement
Citations:
PubMed Identifier
16864853
Citation
Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3865-70. doi: 10.1200/JCO.2006.06.2117. Epub 2006 Jul 24.
Results Reference
result
PubMed Identifier
18166803
Citation
Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. doi: 10.3324/haematol.11771.
Results Reference
result
PubMed Identifier
22473593
Citation
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Ann Oncol. 2012 Oct;23(10):2670-2675. doi: 10.1093/annonc/mds059. Epub 2012 Apr 3. Erratum In: Ann Oncol. 2015 Mar;26(3):608-11.
Results Reference
result
PubMed Identifier
18413641
Citation
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. doi: 10.1200/JCO.2007.13.5533. Epub 2008 Apr 14.
Results Reference
result
PubMed Identifier
21745167
Citation
Motomura K, Natsume A, Fujii M, Ito M, Momota H, Wakabayashi T. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma. 2011 Nov;52(11):2069-75. doi: 10.3109/10428194.2011.596967. Epub 2011 Jul 12.
Results Reference
result
PubMed Identifier
27098429
Citation
Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016 Apr 21;16:282. doi: 10.1186/s12885-016-2311-4.
Results Reference
derived
Learn more about this trial
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
We'll reach out to this number within 24 hrs